BioSpace News Archive

Miromatrix Medical Inc. announced its participation in the H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.

Quest Diagnostics, the world’s leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on July 20, 2022 to shareholders of record of Quest Diagnostics common stock on July 6, 2022.

Medical device company Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV™, a tension-activated breakaway safety release valve designed to reduce the risk of IV catheter failure and replacement in hospitals.

SIMCERE PHARMA announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute of Materia Medica and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinical Trial Approval issued by the National Medical Products Administration in China, and is proposed for post-exposure prophylaxis for close contacts of individuals who test positive for SARS-CoV-2.

Nimble Therapeutics Inc. announced the company has achieved the first development milestone for each of several programs attached to a multi-target collaboration with an undisclosed large pharma partner.

Quotient Limited announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.

Scientific Industries, Inc., a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three and nine month periods ended March 31, 2022.

Brachytherapy is a radiotherapy technique in which radioactive devices are implanted near tumor sites to safely delivery high doses of radiation to eliminate and shrink malignant tumors while simultaneously preventing damage to surrounding tissues.

Rising prevalence of chronic disorders such as cancer, increasing infectious disease outbreaks such as the ongoing COVID-19 pandemic, and growing applications of miRNA in the pharmaceutical and biotechnology sectors are other key factors responsible for market growth.

By Application (Hematology, Haemato-Oncology, Rheumatology, Immunology, and Neurology) and By Region Forecast to 2028 market that offers a comprehensive overview of the market and helps investors, users understand market dynamics and make investment plans accordingly. The report offers details about market revenue growth, market size, drivers, restraints, limitations, growth opportunities and top companies.